Genome&Company Adjusts Conversion Price to ₩5,240 from ₩6,420

Genome&Company · KOSDAQ · 314130 · Oct 13, 2026 · Conversion price adjustments

Genome&Company adjusted its conversion price from ₩6,420 to ₩5,240, effective Oct 13, 2026, due to a decline in market price. The number of shares issuable on conversion rose from 4,205,607 shares to 5,152,671 shares, an increase of 22.5% by our calculation.

Key facts

Price before adjustment₩6,420
Price after adjustment₩5,240
Shares before adjustment4,205,607 shares
Shares after adjustment5,152,671 shares
ReasonConversion price adjustment due to decline in market price
Effective dateOct 13, 2026
Increase in shares issuable (calculated)22.5%

Comparison

Revenue 2025₩24.6bn
Revenue 2024₩27.7bn
Revenue 2023₩14.3bn

Context

In the 12 months before this filing, the company issued CB/BW/EB totaling ₩27.0bn. Potential new shares over that period were 5,713,012 shares, or 10.9% of shares, not netting one upward conversion price adjustment.

Key metrics

Potential dilution

CB/BW/EB issued, last 12 months₩27.0bn As of Mar 6, 2026 Source 1 ↗
Rights offering new shares, last 12 months1,507,405 shares As of Apr 3, 2026 Source 1 ↗, Source 2 ↗
Potential new shares, last 12 months6,660,076 shares (1 upward conversion price adjustment not netted) As of Oct 13, 2026 Source 1 ↗, Source 2 ↗, Source 3 ↗, Source 4
Potential new shares, % of shares12.7% (1 upward conversion price adjustment not netted) As of Oct 13, 2026 Source 1 ↗, Source 2 ↗, Source 3 ↗, Source 4, Source 5 ↗
Conversion price adjustments, last 12 months2 As of Oct 13, 2026 Source 1 ↗, Source 2

Source: DART (Financial Supervisory Service) · Original filing on DART ↗ (opens the Financial Supervisory Service's DART site)